Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.

Sun H, Zhu L, Yang H, Qian W, Guo L, Zhou S, Gao B, Li Z, Zhou Y, Jiang H, Chen K, Zhen X, Liu H.

Bioorg Med Chem. 2013 Feb 15;21(4):856-68. doi: 10.1016/j.bmc.2012.12.016. Epub 2012 Dec 21.

PMID:
23332346
2.

Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.

Li Z, Huang J, Sun H, Zhou S, Guo L, Zhou Y, Zhen X, Liu H.

Bioorg Med Chem. 2014 Nov 1;22(21):5838-46. doi: 10.1016/j.bmc.2014.09.024. Epub 2014 Sep 19.

PMID:
25308766
3.

New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.

Liégeois JF, Deville M, Dilly S, Lamy C, Mangin F, Résimont M, Tarazi FI.

J Med Chem. 2012 Feb 23;55(4):1572-82. doi: 10.1021/jm2013419. Epub 2012 Feb 13.

PMID:
22268448
4.

Design, synthesis, and pharmacological evaluation of novel tetrahydroprotoberberine derivatives: selective inhibitors of dopamine D₁ receptor.

Qian W, Lu W, Sun H, Li Z, Zhu L, Zhao R, Zhang L, Zhou S, Zhou Y, Jiang H, Zhen X, Liu H.

Bioorg Med Chem. 2012 Aug 1;20(15):4862-71. doi: 10.1016/j.bmc.2012.05.057. Epub 2012 Jun 5.

PMID:
22748706
5.

'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.

Zhang J, Zhang H, Cai W, Yu L, Zhen X, Zhang A.

Bioorg Med Chem. 2009 Jul 15;17(14):4873-80. doi: 10.1016/j.bmc.2009.06.019. Epub 2009 Jun 16.

PMID:
19559623
6.

Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.

Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.

J Med Chem. 2004 Jan 1;47(1):143-57.

PMID:
14695828
7.

Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist.

Picard M, Morisset S, Cloix JF, Bizot JC, Guerin M, Beneteau V, Guillaumet G, Hevor TK.

Neuroscience. 2010 Sep 1;169(3):1337-46. doi: 10.1016/j.neuroscience.2010.05.040. Epub 2010 May 24.

PMID:
20580787
8.

F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.

Newman-Tancredi A, Assié MB, Martel JC, Cosi C, Slot LB, Palmier C, Rauly-Lestienne I, Colpaert F, Vacher B, Cussac D.

Br J Pharmacol. 2007 May;151(2):237-52. Epub 2007 Mar 20.

9.

Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.

Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY.

Behav Brain Res. 2015 May 15;285:165-75. doi: 10.1016/j.bbr.2014.09.040. Epub 2014 Oct 16.

PMID:
25448429
10.

N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands.

Liu Z, Chen X, Sun P, Yu L, Zhen X, Zhang A.

Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. doi: 10.1016/j.bmc.2008.08.056. Epub 2008 Aug 28.

PMID:
18783955
11.

New 5-hydroxytryptamine(1A) receptor ligands containing a norbornene nucleus: synthesis and in vitro pharmacological evaluation.

Fiorino F, Perissutti E, Severino B, Santagada V, Cirillo D, Terracciano S, Massarelli P, Bruni G, Collavoli E, Renner C, Caliendo G.

J Med Chem. 2005 Aug 25;48(17):5495-503.

PMID:
16107148
12.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.

Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL.

J Pharmacol Exp Ther. 2010 Jan;332(1):190-201. doi: 10.1124/jpet.109.157388. Epub 2009 Oct 14.

13.

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.

Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD.

Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25.

PMID:
17242925
14.

SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.

McCreary AC, Glennon JC, Ashby CR Jr, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG.

Neuropsychopharmacology. 2007 Jan;32(1):78-94. Epub 2006 May 17.

15.

Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.

Carro L, Raviña E, Domínguez E, Brea J, Loza MI, Masaguer CF.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6059-62. doi: 10.1016/j.bmcl.2009.09.041. Epub 2009 Sep 17.

PMID:
19796944
16.

Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.

Zajdel P, Subra G, Bojarski AJ, Duszyńska B, Tatarczyńska E, Nikiforuk A, Chojnacka-Wójcik E, Pawłowski M, Martinez J.

Bioorg Med Chem. 2007 Apr 15;15(8):2907-19. Epub 2007 Feb 13.

PMID:
17321139
17.

l-Stepholidine-induced excitation of dopamine neurons in rat ventral tegmental area is associated with its 5-HT(1A) receptor partial agonistic activity.

Gao M, Chu HY, Jin GZ, Zhang ZJ, Wu J, Zhen XC.

Synapse. 2011 May;65(5):379-87. doi: 10.1002/syn.20855. Epub 2010 Sep 24.

PMID:
20803620
18.

Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.

Jantschak F, Brosda J, Franke RT, Fink H, Möller D, Hübner H, Gmeiner P, Pertz HH.

J Pharmacol Exp Ther. 2013 Oct;347(1):57-68. doi: 10.1124/jpet.113.205997. Epub 2013 Jul 17.

19.

Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.

Butini S, Gemma S, Campiani G, Franceschini S, Trotta F, Borriello M, Ceres N, Ros S, Coccone SS, Bernetti M, De Angelis M, Brindisi M, Nacci V, Fiorini I, Novellino E, Cagnotto A, Mennini T, Sandager-Nielsen K, Andreasen JT, Scheel-Kruger J, Mikkelsen JD, Fattorusso C.

J Med Chem. 2009 Jan 8;52(1):151-69. doi: 10.1021/jm800689g.

PMID:
19072656
20.

Supplemental Content

Support Center